Adalimumab biosimilar - mAbxience
Latest Information Update: 02 Aug 2016
At a glance
- Originator mAbxience
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
- Mechanism of Action Tumour necrosis factor alpha inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 02 Aug 2016 Preclinical trials in Rheumatoid arthritis in Spain (SC)